CN103502231A - 用于稠合氨基二氢噻嗪衍生物的合成的方法和化合物 - Google Patents

用于稠合氨基二氢噻嗪衍生物的合成的方法和化合物 Download PDF

Info

Publication number
CN103502231A
CN103502231A CN201280004193.7A CN201280004193A CN103502231A CN 103502231 A CN103502231 A CN 103502231A CN 201280004193 A CN201280004193 A CN 201280004193A CN 103502231 A CN103502231 A CN 103502231A
Authority
CN
China
Prior art keywords
compound
salt
mixture
formula
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280004193.7A
Other languages
English (en)
Chinese (zh)
Inventor
B.米塔塞夫
金大式
张慧明
M.J.施纳德贝克
C.N.法兴
K.尤施扎瓦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanitary Material R&d Management Co ltd
Original Assignee
Sanitary Material R&d Management Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanitary Material R&d Management Co ltd filed Critical Sanitary Material R&d Management Co ltd
Priority to CN201610875412.9A priority Critical patent/CN106632401B/zh
Publication of CN103502231A publication Critical patent/CN103502231A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/22—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
CN201280004193.7A 2011-01-21 2012-01-20 用于稠合氨基二氢噻嗪衍生物的合成的方法和化合物 Pending CN103502231A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610875412.9A CN106632401B (zh) 2011-01-21 2012-01-20 用于稠合氨基二氢噻嗪衍生物的合成的方法和化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161434849P 2011-01-21 2011-01-21
US61/434,849 2011-01-21
PCT/US2012/022053 WO2012100179A1 (en) 2011-01-21 2012-01-20 Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610875412.9A Division CN106632401B (zh) 2011-01-21 2012-01-20 用于稠合氨基二氢噻嗪衍生物的合成的方法和化合物

Publications (1)

Publication Number Publication Date
CN103502231A true CN103502231A (zh) 2014-01-08

Family

ID=45563570

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280004193.7A Pending CN103502231A (zh) 2011-01-21 2012-01-20 用于稠合氨基二氢噻嗪衍生物的合成的方法和化合物
CN201610875412.9A Expired - Fee Related CN106632401B (zh) 2011-01-21 2012-01-20 用于稠合氨基二氢噻嗪衍生物的合成的方法和化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610875412.9A Expired - Fee Related CN106632401B (zh) 2011-01-21 2012-01-20 用于稠合氨基二氢噻嗪衍生物的合成的方法和化合物

Country Status (12)

Country Link
US (3) US8426584B2 (cg-RX-API-DMAC7.html)
EP (1) EP2665716B1 (cg-RX-API-DMAC7.html)
JP (2) JP5993875B2 (cg-RX-API-DMAC7.html)
CN (2) CN103502231A (cg-RX-API-DMAC7.html)
BR (1) BR112013016241A2 (cg-RX-API-DMAC7.html)
CA (1) CA2814014A1 (cg-RX-API-DMAC7.html)
ES (1) ES2624288T3 (cg-RX-API-DMAC7.html)
IL (1) IL226405A0 (cg-RX-API-DMAC7.html)
MX (1) MX2013005115A (cg-RX-API-DMAC7.html)
RU (1) RU2013138226A (cg-RX-API-DMAC7.html)
SG (2) SG10201601516QA (cg-RX-API-DMAC7.html)
WO (1) WO2012100179A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106568A (zh) * 2014-10-10 2017-08-29 卫材R&D管理有限公司 稠合氨基二氢噻嗪衍生物的药物组合物

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2233474T3 (pl) 2008-01-18 2015-12-31 Eisai R&D Man Co Ltd Skondensowana pochodna aminodihydrotiazyny
GB0912777D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydropyrimidone derivatives
GB0912778D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101139D0 (en) * 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101140D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
UY34278A (es) 2011-08-25 2013-04-05 Novartis Ag Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
GB201212816D0 (en) * 2012-07-19 2012-09-05 Eisai Ltd Novel compounds
JO3318B1 (ar) 2013-06-18 2019-03-13 Lilly Co Eli مثبطات bace
BR112019008359A2 (pt) 2016-10-27 2019-10-01 Eisai R&D Man Co Ltd método para tratamento da doença de alzheimer, e, composição farmacêutica.
US20210324056A1 (en) 2018-07-24 2021-10-21 Eisai R&D Management Co., Ltd. Methods of treatment and prevention of alzheimer's disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101910143A (zh) * 2008-01-18 2010-12-08 卫材R&D管理有限公司 稠合的氨基二氢噻嗪衍生物
WO2011005738A1 (en) * 2009-07-09 2011-01-13 Eli Lilly And Company Bace inhibitors

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3235551A (en) 1966-02-15 Novel derivatives of
US3227713A (en) 1966-01-04 Azine derivatives
JPH0967355A (ja) 1995-08-31 1997-03-11 Tokyo Tanabe Co Ltd チアジン誘導体、チアゾール誘導体及びそれらの製造方法
CA2407088A1 (en) 2000-05-19 2001-11-22 Takeda Chemical Industries, Ltd. Beta-secretase inhibitors
US6562783B2 (en) 2001-05-30 2003-05-13 Neurologic, Inc. Phosphinylmethyl and phosphorylmethyl succinic and glutauric acid analogs as β-secretase inhibitors
WO2004014843A1 (ja) 2002-08-09 2004-02-19 Takeda Chemical Industries, Ltd. 置換アミノ化合物およびその用途
AU2003285012A1 (en) 2002-10-24 2004-05-13 Sepracor, Inc. Compositions comprising zopiclone derivatives and methods of making and using the same
JP2004149429A (ja) 2002-10-29 2004-05-27 Takeda Chem Ind Ltd インドール化合物およびその用途
ATE443043T1 (de) 2002-11-12 2009-10-15 Merck & Co Inc Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
EP2335701B1 (en) 2003-12-15 2012-07-11 Schering Corporation Heterocyclic aspartyl protease inhibitors
JP2007530696A (ja) 2004-03-30 2007-11-01 メルク　エンド　カムパニー　インコーポレーテッド アスパラギン酸プロテアーゼ阻害剤として有用な２−アミノチアゾール化合物
PE20060664A1 (es) 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
EP1802588A4 (en) 2004-10-15 2010-02-17 Astrazeneca Ab SUBSTITUTED AMINOPYRIMIDONE AND APPLICATIONS THEREOF
JP2008516945A (ja) 2004-10-15 2008-05-22 アストラゼネカ・アクチエボラーグ 置換されたアミノ化合物およびそれらの使用
CA2594946A1 (en) 2005-01-19 2006-07-27 Merck & Co., Inc Tertiary carbinamines having substituted heterocycles, which are active as inhibitors of beta-secretase, for the treatment of alzheimer's disease
PE20070135A1 (es) 2005-06-14 2007-03-09 Schering Corp Compuestos heterociclicos como inhibidores de aspartil proteasas
JP2009502786A (ja) 2005-07-18 2009-01-29 メルク エンド カムパニー インコーポレーテッド アルツハイマー病を治療するためのスピロピペリジンβ−セクレターゼ阻害剤
CA2628074C (en) 2005-10-25 2014-01-14 Shionogi & Co., Ltd. Aminodihydrothiazine derivative
CN101460480A (zh) 2006-04-05 2009-06-17 阿斯利康(瑞典)有限公司 2-氨基嘧啶-4-酮类化合物及其用于治疗或预防Aβ相关病理的用途
AU2007268507B2 (en) 2006-05-31 2012-01-19 Daiichi Sankyo Company, Limited Seven-membered ring compound, production method thereof and pharmaceutical use thereof
JP2010512389A (ja) 2006-12-12 2010-04-22 シェーリング コーポレイション アスパルチルプロテアーゼ阻害剤
JP5383484B2 (ja) 2007-04-24 2014-01-08 塩野義製薬株式会社 環式基で置換されたアミノジヒドロチアジン誘導体
US8653067B2 (en) 2007-04-24 2014-02-18 Shionogi & Co., Ltd. Pharmaceutical composition for treating Alzheimer's disease
AU2008255733B8 (en) 2007-05-29 2013-06-13 Santen Pharmaceutical Co., Ltd. Novel 1,2,3,4-tetrahydroquinoxaline derivative which has, as substituent, phenyl group having sulfonic acid ester structure or sulfonic acid amide structure introduced therein and has glucocorticoid receptor-binding activity
PE20091236A1 (es) 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
TWI431004B (zh) 2008-05-02 2014-03-21 Lilly Co Eli Ｂａｃｅ抑制劑
WO2010013302A1 (ja) 2008-07-28 2010-02-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 スピロアミノジヒドロチアジン誘導体
CN102105475B (zh) 2008-07-28 2014-04-09 卫材R&D管理有限公司 螺氨基二氢噻嗪衍生物
JP5666304B2 (ja) 2008-09-30 2015-02-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 新規な縮合アミノジヒドロチアジン誘導体
GB0912778D0 (en) * 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
GB0912777D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydropyrimidone derivatives
US20130085131A1 (en) 2010-07-01 2013-04-04 Amgen Inc. Heterocyclic compounds and their uses
GB201101140D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101910143A (zh) * 2008-01-18 2010-12-08 卫材R&D管理有限公司 稠合的氨基二氢噻嗪衍生物
WO2011005738A1 (en) * 2009-07-09 2011-01-13 Eli Lilly And Company Bace inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LINDA DOYLE ET AL.: "An investigation of structure-reactivity relationships of d-alkenyl oximes; competitive thermal reactions leading to cyclic nitrones and/or N-unsubstituted bicyclic isoxazolidines", 《TETRAHEDRON》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106568A (zh) * 2014-10-10 2017-08-29 卫材R&D管理有限公司 稠合氨基二氢噻嗪衍生物的药物组合物
CN107106568B (zh) * 2014-10-10 2023-09-26 卫材R&D管理有限公司 稠合氨基二氢噻嗪衍生物的药物组合物

Also Published As

Publication number Publication date
WO2012100179A1 (en) 2012-07-26
ES2624288T3 (es) 2017-07-13
US8426584B2 (en) 2013-04-23
CA2814014A1 (en) 2012-07-26
CN106632401A (zh) 2017-05-10
MX2013005115A (es) 2013-06-03
EP2665716B1 (en) 2017-03-08
SG10201601516QA (en) 2016-03-30
US8962858B2 (en) 2015-02-24
RU2013138226A (ru) 2015-02-27
JP2016121177A (ja) 2016-07-07
CN106632401B (zh) 2020-12-29
EP2665716A1 (en) 2013-11-27
US8802871B2 (en) 2014-08-12
BR112013016241A2 (pt) 2016-07-12
JP2014503001A (ja) 2014-02-06
US20120190848A1 (en) 2012-07-26
JP5993875B2 (ja) 2016-09-14
JP6087005B2 (ja) 2017-03-01
US20140309429A1 (en) 2014-10-16
SG191710A1 (en) 2013-08-30
US20130197244A1 (en) 2013-08-01
IL226405A0 (en) 2013-07-31

Similar Documents

Publication Publication Date Title
CN106632401B (zh) 用于稠合氨基二氢噻嗪衍生物的合成的方法和化合物
AU2009205072C1 (en) Condensed aminodihydrothiazine derivative
MX2012000510A (es) Inhibidores de bace.
TW201623236A (zh) 吡唑醯胺衍生物
CN111511357A (zh) 用于制备他品洛夫的方法
EP2935256A1 (en) 4,6-diarylaminothiazines as bace1 inhibitors and their use for the reduction of beta-amyloid production
CA2804137C (en) Fused heterocyclic derivatives as s1p modulators
WO2019036441A1 (en) PROCESSES FOR PREPARING NIRAPARIB AND INTERMEDIATES THEREOF
US20230416252A1 (en) Process toward the manufacture of (6r,10s)-10-{4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)-pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazolo[4,3-b][1,7]diazacyclotetradecin-5(6h)-one
EP1817312A1 (en) Macrocyclic aminopyridyl beta-secretase inhibitors for the treatment of alzheimer's disease
WO2014015125A1 (en) Fused aminodihydrothiazine derivative salts and uses thereof
JP6723250B2 (ja) Ｎ−［３−［（４ａｒ，７ａｓ）−２−アミノ−６−（５−フルオロピリミジン−２−イル）−４，４ａ，５，７−テトラヒドロピロロ［３，４−ｄ］［１，３］チアジン−７ａ−イル］−４−フルオロ−フェニル］−５−メトキシ−ピラジン−２−カルボキサミドのトシル酸塩
TW200530178A (en) Processes for preparing bicyclo [3.1.0] hexane derivatives, and intermediates thereto
JPWO2012157504A1 (ja) β−ラクタム化合物およびその製造方法
JPH05221947A (ja) シクロプロパン誘導体の製法
TW202607005A (zh) 用於治療與apj受體活性相關的病狀的化合物及組成物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20140108